Filters
Documents
Showing 25 of 922 items meeting your criteria.
| Type | Category | Supplier | ||
|---|---|---|---|---|
 | Elabscience provides a range of products for the study of oxidative stress. | |||
Documents | Metabolism | Elabscience | ||
 | Elabscience provides a range of products for the study of energy metabolism. | |||
Documents | Metabolism | Elabscience | ||
 | Elabscience provides a range of research tools for application in Diabetes studies. | |||
Documents | Metabolism | Elabscience | ||
 | Abnova provides integrated Antibody LNP Conjugation Services to support research and preclinical development programs. Their capabilities include the use of customer-provided or Abnova-generated antibodies, LNP formulation development, and conjugation strategy optimisation. Leveraging expertise in antibodies, RNA technologies, and nanoparticle development, we deliver customised solutions tailored to diverse research and therapeutic applications. | |||
Documents | Service | Abnova Corporation | ||
 | Cancer remains one of the most active areas of biomedical research, driving continuous advances in immunotherapy, targeted therapeutics, biomarker discovery, and precision medicine. To support cancer research from basic biology to translational studies, Abnova offers a comprehensive portfolio of antibodies, recombinant proteins, and ELISA kits covering key oncology pathways and targets.
This catalog highlights antibodies, recombinant proteins, and ELISA kits supporting research in Immuno-Oncology, Cell Therapy, Targeted Therapy, Biomarkers, DNA Repair, Tumor Microenvironment, Cell Signaling, Cancer Stem Cells, Tumor Suppressors, Cell Death, Hematologic Oncology, and Cancer Metabolism. Our products are designed to support studies in tumor biology, immune regulation, therapeutic target validation, biomarker development, and drug discovery. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova offers a comprehensive portfolio of proteins, antibodies, and ELISA kits to support infectious disease research across a wide range of pathogens, including viruses, bacteria, protozoans, parasites, and fungi. Their products are designed to enable reliable detection, characterisation, and quantification of disease-related targets, supporting applications from basic research to translational studies. With high specificity, sensitivity, and consistent performance, our reagents facilitate efficient assay development and reproducible results. Explore our curated selection to advance your research in pathogen biology, host–pathogen interactions, and diagnostic development. | |||
Documents | Immunology | Abnova Corporation | ||
 | Next-generation miRNA inhibition with enhanced stability and performance | |||
Documents | RNA | Abnova Corporation | ||
 | Biologics development requires accurate quantification and reliable immunogenicity assessment to ensure safety and efficacy. Abnova provides Biosimilar and Immunogenicity Research Tools to support key workflows from drug measurement to immune response evaluation.
Abnovas portfolio includes biosimilar antibodies and ELISA kits for comparative and PK studies, as well as ADA reagents and ELISA kits for immunogenicity assessment. These solutions provide high sensitivity and reproducibility, enabling efficient and consistent research outcomes. | |||
Documents | Immunology | Abnova Corporation | ||
 | The acquisition and transport of fresh human tissues impose stringent logistical and biological constraints that directly impact downstream model fidelity. High-specification samples remain scarce, must be accepted within hours of resection, and exhibit rapid viability and phenotypic decay when held in conventional liquid media, leaving a narrow window for QC, allocation, and delivery. These constraints frequently lead to sample loss, reduced cellular yield, and compromised microenvironmental integrity before processing can begin. TissueReady™ PLUS addresses these limitations by extending ex vivo stability from <24 hours to up to 5 days, preserving cell viability, tumour content, and histological and molecular features, thereby enabling more flexible coordination, reduced wastage, and improved reliability of primary tissue-derived model generation. | |||
Documents | Sample Preservation | Atelerix | ||
 | This whitepaper documents how Atelerixs hydrogel technology, CytoStor, can enable hypothermic viral and vaccine stabilisation for cryo-free logistics, providing case examples specifically of SARSCoV-2, Adenovirus, Lentivirus, Lentiviral Vectors, and LNP-mRNA viral vectors. | |||
Documents | Sample Preservation | Atelerix | ||
 | TissueReady PLUS offers a simple solution that preserves the viability and quality of fresh tissue at ambient temperatures, increasing shelf life, enabling shipment, enhancing the
flexibility of workflows and improving the quality of screening and model generation from these tissues. | |||
Documents | Sample Preservation | Atelerix | ||
 | This report provides data to support the storage and transport of organoids using Atelerixs preservation technologies, STORganoid™ and WellReady™. | |||
Documents | Sample Preservation | Atelerix | ||
 | The use of organoids for disease modelling, drug discovery and personalised medicine has become increasingly popular. Processes for the generation and maintenance of organoids can
be complex, requiring high technical awareness. Additionally, some organoid models are unsuitable for storage and shipment by freeze/thaw. WellReady™offers a simple solution to
these challenges, allowing for the shipment of developed organoid models at ambient temperatures, supplying the end-user with a ready to use model. | |||
Documents | Sample Preservation | Atelerix | ||
 | This report provides data to support the integration of Atelerixs technology, LeukoStor, into the CAR-T manufacturing process. | |||
Documents | Sample Preservation | Atelerix | ||
 | This whitepaper demonstrates the preservation of PBMC viability and cell composition after hypothermic storage in Atelerixs product, CytoStor. | |||
Documents | Sample Preservation | Atelerix | ||
 | This report provides data to support the storage and transport of human whole blood by Atelerixs technology, BloodReady™. | |||
Documents | Sample Preservation | Atelerix | ||
 | This data pack references the preservation capabilities of the following products: BeadReady™, BloodReady™, LeukoStor™, TissueReady Plus™, CytoStor™ and WellReady™. | |||
Documents | Sample Preservation | Atelerix | ||
 | A roll through Atelerixs products and amazing applications in ambient biosample preservation. | |||
Documents | Catalogue | Atelerix | ||
 | User guide for In Vivo Imaging with Collagen Hybridizing Peptides (sCy7.5-CHP In vivo Kit) | |||
Documents | Datasheets | 3Helix | ||
 | The Portfolio: F-CHP, R-CHP, B-CHP, sCy7.5-CHP | |||
Documents | Peptides | 3Helix | ||
 | Collagen Hybridizing Peptides (CHPs) selectively bind to the damaged collagen molecules that signify the onset of tissue injury, giving you the power to: Detect Damage Earlier, Get Definitive Proof, Monitor Damage in Real-Time.
Collagen Hybridizing Peptides (CHPs) selectively target sites of active collagen remodeling, metabolic activity that is a hallmark of fibrosis, inflammation, cell invasion, and more, giving you the power to: Visualize Active Remodeling, Quantify Disease Activity, Monitor Therapeutic Response. | |||
Documents | Peptides | 3Helix | ||
 | T he dense stromal reaction in PDAC, rich in collagen, profoundly impacts tumor progression and drug delivery. Aberrant collagen remodeling is a hallmark of this aggressive cancer. Collagen Hybridizing Peptides (CHPs), with their unique ability to target denatured collagen, offer a powerful tool to visualize and quantify these critical structural changes within the PDAC microenvironment. This technology can enhance our understanding of stromal biology and potentially identify novel therapeutic strategies. | |||
Documents | Peptides | 3Helix | ||
 | The ability of CHPs to specifically target and visualize active fibrosis offers several important implications for nAMD research. Firstly, they serve as a novel tool for understanding the dynamics of fibrosis in the disease process, potentially identifying key stages for intervention. Secondly, CHPs can accelerate the development of new anti-fibrotic treatments by providing a direct and quantifiable measure of drugefficacy in preclinical studies. Finally, while currently primarily used in animal models, the potential exists to translate CHP technology into diagnostic tools for human patients, allowing for earlier detection and monitoring of subretinal fibrosis, which could ultimately lead to improved treatment strategies and visual outcomes. | |||
Documents | Peptides | 3Helix | ||
 | Collagen Hybridizing Peptides (CHPs) for Monitoring ECM Changes Resulting From Myocardial Infarction Collagen Hybridizing Peptides (CHPs), with their specific affinity for denatured collagen, are a unique tool which can address limitations in Myocardial Infarction research by enabling enhanced visualization and quantification of structural collagen changes associated with Myocardial Infarction. | |||
Documents | Peptides | 3Helix | ||
 | Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease characterized by extensive damage to the collagen within lung tissue. This damage triggers excessive collagen deposition and aberrant extracellular matrix (ECM) remodeling, ultimately leading to lung stiffening and a decline in lung function. While the overabundance of collagen is a hallmark of IPF, the dynamic processes of collagens ongoing damage and remodeling have been less understood. Collagen Hybridizing Peptides (CHPs) allow researchers to probe and visualize areas where collagen is being actively remodeled. The application of CHPs is expanding our understanding of how collagen damage contributes to IPF pathology and opening
new avenues for diagnosis and therapy. | |||
Documents | Peptides | 3Helix | ||